The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.03% of ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.